Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Bubs Australia founder and CEO forced out for alleged failure to comply with board directions
    • News

    Bubs Australia founder and CEO forced out for alleged failure to comply with board directions

    Just a month after Bubs Australia (ASX: BUB) announced that executive chairman Dennis Lin would be removed from the business, the baby milk formula company announced another shake up of its executive line up. Perhaps a foreseeable one, this time founder and CEO Kristy Carr was terminated from her position with immediate effect due to

    Read More
    Public
  • Appen share price falls over 20% after disappointing April update
    • News

    Appen share price falls over 20% after disappointing April update

    Machine intelligence company Appen (ASX: APX) must be having Covid flashbacks as its share price is tanking once again. Once an ASX dreamboat, falling demand for the Company’s products has left it to take on cost reduction initiatives. In February 2023, in its annual report, Appen stated that it expects a soft start to FY23

    Read More
    Public
  • The Redbubble bubble bursts with mass layoffs underlining the quarter
    • News

    The Redbubble bubble bursts with mass layoffs underlining the quarter

    Over the past year, tech companies in the US have become notorious for mass layoffs. IT giants, from Google to Amazon, have laid off thousands of employees in light of growing inflation. Now, that trend seems to be gaining steam in Australia.  To return to cash flow positivity, Aussie online print-on-demand marketplace Redbubble (ASX: RBL)

    Read More
    Public
  • Shares continue to tread water as they wait on data
    • Market Update

    Shares continue to tread water as they wait on data

    The XJO is expected to edge lower on open this morning following a similar move from the U.S last night and their flat futures this morning. Markets are simply quiet heading into the CPI reading tonight in the U.S. Locally, we had the federal budget released last night. We don’t see this affecting our market

    Read More
    Public
  • Proteomics’ PromarkerD test enters the lucrative US market
    • News

    Proteomics’ PromarkerD test enters the lucrative US market

    Successful early diagnosis of diabetic kidney disease (DKD) delivers a win-win-win situation for the medical professionals who treat this disease, its sufferers and the cost base of any country’s health system. Doctors would gain access to speedier diagnosis, opening the way for them to deliver more efficacious treatment decisions that improve clinical outcomes for patients,

    Read More
    Public
  • Drug that stops growth of cancerous cells shows positive results
    • News

    Drug that stops growth of cancerous cells shows positive results

    12-year-old Louie the beagle had little time left once the vet diagnosed his lymphoma. To avoid the side effects of steroids and chemo, his parents took a chance on biotech company PharmAust’s (ASX: PAA) monepantel (MPL) drug. Within a few weeks, Louie’s lymph nodes shrunk and he enjoyed a good quality of life. Today, he

    Read More
    Public
  • «
  • ‹
  • 246
  • 247
  • 248
  • 249
  • 250
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.